The FDA has approved tirzepatide (Zepbound) as the first and only medication for obstructive sleep apnea in adults with obesity. Clinical trials revealed that tirzepatide achieved an average weight ...

The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer (NSCLC). Backed by robust data from the TROPION-Lung05 ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...

Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...

The latest findings presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) reveal that patients with germline BRCA-mutated, HER2-negative breast cancer who received one year of the oral ...

Synaffix announces that it has entered into a licensing agreement with Elevation Oncology to develop EO-1022, a HER3-targeting Antibody-Drug Conjugate (ADC) leveraging Synaffix’s advanced platform ...

The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends progression-free survival (PFS) in HR+, HER2+ metastatic breast cancer.

Merck has announced a significant milestone in the treatment of advanced epithelial ovarian cancer. The Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) plus chemotherapy, ...

The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival (PFS) in untreated chronic lymphocytic leukemia (CLL). With 77% of patients ...

The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant metastatic colorectal cancer. The Phase 3 BREAKWATER trial showed ...

We have honored to host Dr. Sara Naseri, CEO and Co-Founder of Qvin, a pioneering figure in women’s health innovation. In this session, we explore the groundbreaking Q-Pad technology, the first ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Bizengri® (zenocutuzumab-zbco), a first-in-class bispecific antibody targeting NRG1+ pancreatic adenocarcinoma and NRG1+ ...